Lung cancer: Gary Middleton interview with Chris

After suffering a persistent cough, Chris was diagnosed with lung cancer following a scan, which revealed the cancer was inoperable due to its position. He found and was enrolled on what turned out to be the practise-changing open label Phase III KEYNOTE-024 clinical trialcomparing treatment with chemotherapy versus an immune checkpoint blockade drug (Pembrolizumab) run locally by Prof Middleton, and was assigned to the Pembrolizumab arm of the trial. Treatment progressed with only very minor side effects initially (Grade 1), and scans revealed significant tumour shrinkage. However, he later developed kidney dysfunction (Grade 2), which necessitated him stopping treatment. He has remained cancer free since.

For Canvas related technical support please see the 24/7. The 'Help' icon on the left-hand navigation

© copyright of University of Birmingham